CMS Open Payments · Program Year 2024
Dexcom, Inc.
Dexcom, Inc. reported $19,345,835.70 across General Payments, Research, and Ownership to 55,653 physicians and teaching hospitals across 56,186 transactions.
- $19.3M Top 10% payer
- All-tracks total
- 56,186 Top 10% volume
- Transactions
- 55,653 Top 10% reach
- Recipients
- −$1.4M
- General Payments vs PY2023
Dexcom, Inc. reported $19,345,835.70 across all CMS Open Payments tracks (General + Research + Ownership) to 55,653 physicians and teaching hospitals in Program Year 2024 - ranking #95 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $2,880,042.15, averaging $347.62 per recipient.
How Dexcom, Inc.'s $19.3M all-tracks total breaks down
Dexcom, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
91/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer dexcom-inc Dexcom, Inc.
$19.3M · #95/1,925 · 0.1% industry · PY2024
- TOT $19.3M
- RANK #95
- SHARE 0.1%
- TXN 56,186
- RCP 55,653
- CAT 5
- GEN $2.9M
- ΔGEN −$1.4M
- TOP1 11.9%
- PY 2024
Volume peers
Nearest volume peer: Vantis Vascular, Inc. ($19.8M)
Dexcom, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Dexcom, Inc.'s CMS-reported General Payments decreased by $1.4M (−33.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: DEXCOM, INC.PY2023: DEXCOM, INC.PY2024: Dexcom, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $4,318,428.68
- PY2024
- $2,880,042.15
What the Data Shows for Dexcom, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Dexcom, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
54,719 transactions worth $1.3M make "Food and Beverage" the top general-payment category in the 5-category breakdown below, 46.2% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Dexcom, Inc. made 5 types of general payments. "Food and Beverage" is the largest category at $1.3M, 46.2% of General Payments.
Dexcom, Inc. reports 5 general-payment categories - the top three are Food and Beverage (46.2%), Compensation for Faculty or Speaker (Medical Education) (37.0%), and Consulting Fee (11.9%). The remaining 2 categories make up 4.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Dexcom, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $1.3M | 54,719 | 46.2% |
| Compensation for Faculty or Speaker (Medical Education) | $1.1M | 464 | 37.0% |
| Consulting Fee | $341.7K | 1 | 11.9% |
| Travel and Lodging | $142.0K | 465 | 4.9% |
| Education | $66.68 | 4 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $505,591.37 (17.6%) of $2,880,042.15 in this company's General Payments records across 28,165 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Dexcom, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Eric Topol
$343,387.54 across 5 reported transactions
- 2
Nicholas Argento
$55,460.17 across 98 reported transactions
- 3
Catherine R Kilpatrick
$36,915.54 across 37 reported transactions
- 4
Pablo F Mora
$35,852.78 across 51 reported transactions
- 5
Timothy R Gilbert
$33,975.34 across 36 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Dexcom, Inc. ranks #95 of 1,925 by total payments (top 5% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,595 of 1,838 by HHI (bottom 13% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Sekisui Diagnostics, LLC : $21.5K total payments, HHI 171
- Baxter Healthcare : $4.8M total payments, HHI 171
- Fresenius USA Marketing, Inc. : $709.1K total payments, HHI 171
- Alpha Orthopedic Systems : $28.4K total payments, HHI 169
- Calliditas Therapeutics US Inc. : $2.0M total payments, HHI 169
- National Marrow Donor Program : $4.2M total payments, HHI 169
- Dexcom, Inc. (this company) : $2.9M total payments, HHI 168
- Gilead Sciences, Inc. : $39.6M total payments, HHI 168
- Catalyst Pharmaceuticals, Inc. : $1.1M total payments, HHI 167
- Organogenesis Inc. : $2.1M total payments, HHI 167
- Sensus Healthcare, Inc. : $4.7K total payments, HHI 165
- Neos Therapeutics, LP : $163.6K total payments, HHI 165
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Dexcom, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Dexcom, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Dexcom, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
AngioDynamics, Inc.
Encore Medical, LP
Neurocrine Biosciences, Inc.
UCB, Inc.
Sun Pharmaceutical Industries Inc.
Put this to use
Dexcom, Inc. ranks #95 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Dexcom, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Dexcom, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.